WUXI – November 05, 2026 -- NORROY BIOSCIENCE presented its radiopharmaceutical pipelines in eight Top Rated Oral Presentations and three e-posters at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM'26), held October 17-21 in Vienna, Austria. The China-based, late-stage clinical biotech also reached preliminary cooperation intentions with Esente Healthcare and other international partners on radiopharmaceutical automation equipment.
NORROY cites two China-originated firsts in its pipeline
The company said its pipeline includes the first China-originated innovative radiopharmaceutical to receive both Breakthrough Therapy Designation (BTD) and Fast Track Designation (FTD). It also named the first China-originated terbium-161-based radiopharmaceutical for prostate cancer. The company stressed that its candidates are investigational and unapproved by the FDA or other regulators, and that BTD and FTD do not guarantee approval.
The data covered diagnostic and therapeutic radionuclides 18F, 68Ga and 177Lu, plus the next-generation therapeutic isotope 161Tb. Targets included ACP3 and GPC3. Indications ranged from prostate cancer and renal cell carcinoma to hepatocellular carcinoma, neuroendocrine tumors, small cell lung cancer and primary aldosteronism.
Prostate cancer data centers on NYM032 and an ACP3-targeted candidate
Oliver Sartor, M.D., Chairman of NORROY's Scientific Advisory Board, delivered an oral presentation on the initial safety and efficacy of 177Lu-NYM032 in progressive metastatic castration-resistant prostate cancer (mCRPC) in a Phase I-II study. NORROY also presented a preliminary first-in-human, low-dose study of 161Tb-labeled NYM032 in mCRPC patients. Research on the ACP3-targeted candidate 68Ga/177Lu-NY129 explored its potential in prostate cancer molecular imaging.
CAIX imaging studies target clear cell renal cell carcinoma
NORROY presented several studies on carbonic anhydrase IX (CAIX)-targeted imaging in clear cell renal cell carcinoma. Work on 68Ga-NYM096 covered lesion detection, one-stop-shop imaging for von Hippel-Lindau syndrome and characterization of cystic renal masses. A second tracer, 18F-NYM124, was evaluated in a prospective head-to-head comparison with 18F-FDG PET/CT.
Other presentations covered:
- Preclinical evaluation of 68Ga/177Lu-NY123, a GPC3-targeted radiotheranostic candidate for hepatocellular carcinoma
- 68Ga-NYM184, a CXCR4-targeted PET radiotracer
- 177Lu-NYM158, an SSTR2-targeted candidate under investigation for aggressive neuroendocrine neoplasms and small cell lung cancer
KUNLUN SALON forum produces automation partnership intentions
NORROY hosted its KUNLUN SALON ecosystem forum during the congress, chaired by Chief Business Officer Thomas Tulip, Ph.D. Sartor also took part. The preliminary cooperation intentions with Esente Healthcare and other international partners focus mainly on developing radiopharmaceutical automation equipment.
Booth 267 pairs drug pipeline with production hardware
At booth 267, NORROY showed an integrated "Radiopharmaceuticals + Equipment" strategy spanning AI-enabled drug discovery, automated manufacturing and unmanned production support systems. The equipment on display included the Mortenon M1 multifunctional synthesis module, the Mortenon P1 automated production line, the Mortenon S3/S4 radionuclide dispensing modules and the Mortenon D2 radiopharmaceutical transport containers.